Houston, TX (PRWEB) April 24, 2013 -- Pharm-Olam International, a multinational full-service Contract Research Organization (CRO) to the pharmaceutical and biotech industries, announced the successful completion of a Phase 3 ophthalmology study in conjunction with InSite Vision.
As the CRO for InSite Vision, Pharm-Olam managed the Phase 3 clinical study to verify the efficacy of BromSite™ (ISV-303) for the reduction of inflammation and pain after cataract surgery. The study included the enrollment and management of 268 patients undergoing cataract surgery in a two-arm trial designed to evaluate the efficacy and safety of BromSite. Patients were randomized and then dosed twice a day beginning the day before surgery and continuing the day of surgery and for 14 days post-surgery. The primary study endpoint was the reduction of inflammation after surgery.
Cataract surgery is the most frequently performed ocular surgery in the United States, with more than three million procedures occurring annually. Typically, anti-inflammatory eye drops are prescribed to reduce pain and inflammation both before and after surgery.
John Hovre, Chief Operating Officer at Pharm-Olam commented, “Our client, InSite Vision, was very pleased with the positive results of the BromSite™ study. We wish InSite Vision the best in their continued study efforts and we look forward to working with them on future projects in the ophthalmic space.”
For further information about Pharm-Olam, please visit http://www.pharm-olam.com.
About Pharm-Olam International
Pharm-Olam International is a multinational contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.
About InSite Vision
InSite Vision is advancing new ophthalmic products for unmet eye care needs based on its innovative DuraSite® platform technologies. The DuraSite and DuraSite 2® drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.
For further information on InSite Vision, please visit http://www.insitevision.com.
